Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients With MGMT Unmethylated Glioblastoma

NCT05986851 is registered in ClinicalTrials.gov with Cantex Pharmaceuticals as lead sponsor.

NCT NCT05986851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05986851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients With MGMT Unmethylated Glioblastoma
Lead sponsor
Cantex Pharmaceuticals
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 12, 2023
Completion date
December 30, 2026
Enrollment
30 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma